In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Lina Eliasson PhD CPsycho, Founding Partner at Sprout Health Solutions, to discuss how pharma companies of all sizes can build a comprehensive, patient-centric evidence strategy that spans the entire drug development pathway. Together, they examine the growing role of COA and in-study interviews in regulatory decision-making, the practical barriers to earlier patient engagement. They explore how eCOA providers could add greater value by getting involved long before a pivotal trial, and a focus on why the choice of data capture modality matters far more than the industry currently recognizes.
In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with RJ Wirth, CEO and Consulting Psychometrician...
In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Stacie Hudgens, Chief Scientific and Strategy...
Artificial intelligence is redefining what’s possible across the clinical development lifecycle, but with rapid innovation comes the need for thoughtful oversight. In this episode...
